Phio Pharmaceuticals Past Earnings Performance
Past criteria checks 0/6
Phio Pharmaceuticals's earnings have been declining at an average annual rate of -8.5%, while the Biotechs industry saw earnings growing at 16.9% annually. Revenues have been declining at an average rate of 66.7% per year.
Key information
-8.5%
Earnings growth rate
93.6%
EPS growth rate
| Biotechs Industry Growth | -14.6% |
| Revenue growth rate | -66.7% |
| Return on equity | -105.9% |
| Net Margin | n/a |
| Last Earnings Update | 31 Dec 2022 |
Recent past performance updates
No updates
Recent updates
Revenue & Expenses BreakdownBeta
How Phio Pharmaceuticals makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 31 Dec 22 | 0 | -11 | 4 | 7 |
| 30 Sep 22 | 0 | -12 | 5 | 0 |
| 30 Jun 22 | 0 | -12 | 5 | 0 |
| 31 Mar 22 | 0 | -13 | 4 | 0 |
| 31 Dec 21 | 0 | -13 | 5 | 9 |
| 30 Sep 21 | 0 | -12 | 5 | 0 |
| 30 Jun 21 | 0 | -11 | 5 | 0 |
| 31 Mar 21 | 0 | -10 | 5 | 0 |
| 31 Dec 20 | 0 | -9 | 5 | 0 |
| 30 Sep 20 | 0 | -9 | 5 | 0 |
| 30 Jun 20 | 0 | -9 | 5 | 0 |
| 31 Mar 20 | 0 | -9 | 5 | 0 |
| 31 Dec 19 | 0 | -9 | 5 | 0 |
| 30 Sep 19 | 0 | -8 | 4 | 0 |
| 30 Jun 19 | 0 | -7 | 3 | 0 |
| 31 Mar 19 | 0 | -7 | 3 | 0 |
| 31 Dec 18 | 0 | -7 | 3 | 0 |
| 30 Sep 18 | 0 | -8 | 3 | 0 |
| 30 Jun 18 | 0 | -9 | 3 | 0 |
| 31 Mar 18 | 0 | -9 | 4 | 0 |
| 31 Dec 17 | 0 | -12 | 4 | 0 |
| 30 Sep 17 | 0 | -15 | 4 | 0 |
| 30 Jun 17 | 0 | -15 | 4 | 0 |
| 31 Mar 17 | 0 | -14 | 4 | 0 |
| 31 Dec 16 | 0 | -11 | 4 | 0 |
| 30 Sep 16 | 0 | -9 | 3 | 0 |
| 30 Jun 16 | 0 | -10 | 4 | 0 |
Quality Earnings: 44R0 is currently unprofitable.
Growing Profit Margin: 44R0 is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: 44R0 is unprofitable, and losses have increased over the past 5 years at a rate of 8.5% per year.
Accelerating Growth: Unable to compare 44R0's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: 44R0 is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-26.8%).
Return on Equity
High ROE: 44R0 has a negative Return on Equity (-105.9%), as it is currently unprofitable.